THE IMPACT OF METABOLIC SYNDROME ON THE PROGNOSIS AND COURSE OF ENDOMETRIAL CANCER: CLINICAL, BIOCHEMICAL ASPECTS AND THERAPEUTIC APPROACHES
Ключевые слова:
Endometrial cancer, metabolic syndrome, insulin resistance, obesity, prognosisАннотация
Endometrial cancer is one of the most common gynecological malignancies worldwide, with its incidence closely associated with metabolic disorders. Metabolic syndrome, characterized by obesity, insulin resistance, dyslipidemia, and hypertension, has been identified as a significant risk factor influencing the development, progression, and prognosis of endometrial cancer. This article examines the impact of metabolic syndrome on the clinical course and outcomes of endometrial cancer, focusing on underlying biochemical mechanisms and current therapeutic approaches. Evidence suggests that metabolic syndrome contributes to tumor progression through hormonal imbalance, chronic inflammation, and altered metabolic signaling pathways. Understanding these interactions is essential for improving prognosis and developing individualized treatment strategies for patients with endometrial cancer.
Библиографические ссылки
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians. 2020;70(1):7–30.
3. Zhang Y, Liu Z, Yu X, et al. The association between metabolic syndrome and endometrial cancer: A meta-analysis. Gynecologic Oncology. 2016;140(2):343–349.
4. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. The Lancet. 2005;366(9491):1059–1062.
5. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk. Cancer Epidemiology Biomarkers & Prevention. 2002;11(12):1531–1543.
6. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nature Reviews Cancer. 2004;4(8):579–591.
7. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.
8. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochimica et Biophysica Acta. 2013;1831(10):1533–1541.
9. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer. The Lancet. 2008;371(9612):569–578.
10. Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation. Gynecologic Oncology. 2010;116(1):92–98.
